This study is testing a new drug called NTX-1088, alone or with pembrolizumab, for people with advanced solid tumors (cancers that have spread or are hard to treat locally). NTX-1088 is a monoclonal antibody (a type of immune therapy) that targets a specific protein called PVR (CD155) on cancer cells. Pembrolizumab is another immune therapy that helps your body fight cancer. This study aims to find the safest and most effective dose of NTX-1088 and see how well it works. You might be able to join if you have certain advanced solid cancers that are known to have PVR, including specific types of colorectal, liver, stomach, lung, endometrial, or cervical cancer. The main goals are to understand the safety and side effects of the treatments.

Study design

This is a Phase 1, open-label (meaning you and your doctors will know what treatment you are receiving), multi-center study. It plans to enroll 90 participants and has two parts: finding the right dose and then expanding to learn more about its effects.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from screening until 30 days after your last dose of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.